Business Context and Reporting Period
This Form 8-K Current Report was filed by Tandem Diabetes Care, Inc. on June 19, 2024. The filing discloses a material corporate governance event: the appointment of a new senior executive officer.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change is the appointment of Jean-Claude Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos brings prior executive experience from Envista Holdings, Qualcomm Life, Becton Dickinson, and ResMed Inc.
Compensation and Severance Arrangements
The filing details the compensatory arrangements for Mr. Kyrillos under an offer letter dated June 10, 2024:
- Base Salary: $450,203.73 annually.
- Annual Bonus: Target of 60% of base salary, with a performance range of 0% to 200% of target.
- Long-Term Incentives: Target award of 400% of base salary in Restricted Stock Units (RSUs).
- Severance Benefits: In the event of involuntary termination or resignation for "good reason" within 3 months before or 12 months after a change of control, Mr. Kyrillos is entitled to 18 months of base salary continuation and full acceleration of unvested equity awards.
Investor Verification Checklist
- Verify the effective date of the COO appointment (June 21, 2024).
- Review the full text of the Offer Letter and Employment Severance Agreement when filed as exhibits to the Form 10-Q for the quarter ending June 30, 2024.
- Confirm the total potential equity value based on the 400% base salary target and current stock price.
- Monitor future filings for any changes to the executive team or strategic direction under the new leadership.